Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-475 in Homozygous Familial Hypercholesterolemia
NCT00263081Phase 3Terminated
- Sponsor
- Takeda
- Start
- Nov 2005
- Primary completion
- Mar 2007
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in homozygous familial hypercholesterolemia (HoFH) comparing Lapaquistat Acetate with Placebo (2 arms). Primary endpoint: Change from Baseline in Low Density Lipoprotein cholesterol at 12 weeks. Started Nov 2005; status: terminated.
02
Drugs
lapaquistat
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT00263081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00263081.